

## Contraception in Women with Autoimmune and Systemic Inflammatory Disorders: Practical Tips for Clinicians

Elham Manouchehri (PhD)<sup>1,2</sup>, Somayeh Alirezaei (PhD)<sup>3,4</sup>, Zahra Mirfeizi (MD)<sup>3</sup>, Maryam Sahebari (MD)<sup>6\*</sup>

<sup>1</sup> Assistant Professor in Reproductive Health, Department of Midwifery, Faculty of Nursing and Midwifery, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran

<sup>2</sup> Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>3</sup> PhD of Reproductive Health, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>4</sup> Department Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>5</sup> Professor of Rheumatology, Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>6</sup> Professor of Rheumatology, Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

### ARTICLE INFO

Article type:

Commentary

Article History:

Received: 12-Jan-2024

Accepted: 28-Jan-2024

#### ► Please cite this paper as:

Manouchehri E, Alirezaei S, Mirfeizi Z, Sahebari M. Contraception in Women with Autoimmune and Systemic Inflammatory Disorders: Practical Tips for Clinicians. *Journal of Midwifery and Reproductive Health*. 2025; 13(2): 1-4. DOI: 10.22038/JMRH.2024.77455.2297

Autoimmune disorders are common among women of reproductive age, with conditions like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) affecting their peak reproductive years (1). Contraception plays a pivotal role in reproductive health due to potential pregnancy risks associated with disease activity, medication use, and disease-related complications (2). This article discusses the considerations for selecting appropriate contraceptive methods for patients with autoimmune disorders.

The patient's medical condition, tobacco usage, family history of hormone-dependent malignancies, laboratory findings such as antiphospholipid antibodies, and stage of reproductive life should all be taken into consideration when deciding which contraceptive technique to employ (3). In counseling about contraceptive regulations, there are frequently instances where practices and recommendations diverge from current guidelines (4).

In this article, the safety of using various

methods of contraception in people with rheumatic diseases is summarized from reliable sources, including the American college of rheumatology (ACR)/European league against rheumatism (EULAR), and associations of rheumatology specialists in various countries, and the clinical advice in this category is available for clinicians and health service providers.

Contraception in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS): Historically, concerns existed about using hormonal contraceptives in SLE due to fears of worsening disease activity and thrombosis (5). However, emerging evidence suggests that careful planning and individualized contraceptive counseling can mitigate these risks (6). Women with SLE require tailored counseling considering disease activity, thrombotic risk, and antiphospholipid antibody status (7). Contraceptive options such as oral contraceptives, subcutaneous implants, and intrauterine devices (IUDs) are discussed based on the disease activity and thrombotic risk (8).

\* *Corresponding author:* Maryam Sahebari, Professor, Professor of Rheumatology, Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: 09155103124; Email: [sahebarim@mums.ac.ir](mailto:sahebarim@mums.ac.ir)



Copyright © 2023 Mashhad University of Medical Sciences. This work is licensed under a Creative Commons Attribution Noncommercial 4.0 International License <mailto:https://creativecommons.org/licenses/by/3.0/>

The most up-to-date data currently does not demonstrate a risk of increasing disease activity in women with inactive or stable SLE who use hormonal contraception (5).

Contraception involving combined hormones (such as the oral pill, vaginal ring, or transdermal patch) should be avoided in women who have positive antiphospholipid antibodies (aPL) (with or without definite APS) (9).

These women can utilize progestin-only methods (pills, subcutaneous depot injections), although the risk of thrombosis should be considered (9). Long-term use of progesterone injections can raise the risk of osteoporosis. Osteoporosis, fractures, or avascular necrosis of bone are more common in women with SLE or RA, either as a result of the disease or from long-term corticosteroid consumption (10). Use of these methods raises concerns about how hormonal contraception, especially injectable depot medroxyprogesterone acetate (DMPA) contraception, affects bone (5).

IUDs are typically regarded in SLE patients as an effective and low-risk contraceptive alternative, despite the possibility of some risk of associated sexually transmitted (STIs) or pelvic inflammatory disorders (1). Treatment with hormonal contraceptives, such as the levonorgestrel-releasing IUD (LNG-IUD), may be beneficial for women with SLE who have excessive menstrual bleeding or hemorrhagic ovarian cysts due to anticoagulant use or a subsequent onset of thrombocytopenia (11).

Notably, all SLE and/or APS patients can safely use emergency contraception, including IUDs and pills (11).

Contraception in rheumatoid arthritis (RA): RA symptoms often improve during pregnancy, leading to investigations into the impact of contraceptive methods on disease activity (12). While most contraceptive methods are considered safe for women with RA, considerations about bone health, infection risk, and medication interactions are highlighted (13).

All forms of contraception seem to be safe for the majority of RA patients, with the notable exception of progestin-only injectable for those who are at most at risk for osteoporosis (5).

The possibility of infection with IUD insertion, particularly if a woman is taking

immunosuppressive medications, is one of the worries regarding the use of contraception in RA patients. In women with RA, using an IUD has not been associated with a higher risk of pelvic infection (12-13). However, in women with RA who are currently IUD-users the increased Anti-citrullinated protein antibodies (ACPAs) positivity as well as higher ACPAs titers has been suggested (14).

In women with RA who are receiving long-term corticosteroid treatment and who have a history of, or risk factors for, non-traumatic fractures, the risks of using progestin-only injectables might be greater than the advantages, because RA itself can lead to osteoporosis and non-traumatic fractures, in addition to the frequent use of corticosteroids in this condition (7). It should be noted that all RA patients can safely use emergency contraception including IUDs and oral contraceptives (15). Finally, self-insertion methods of contraception like vaginal ring may be challenging for women with joint abnormalities (7).

Thrombocytopenia and contraceptive use: Thrombocytopenia is prevalent among patients with autoimmune disorders, impacting contraceptive choices (16). The association between aPL-positive status and thrombocytopenia is explored, along with potential causes of platelet count reduction (17). The article provides insights into evaluating thrombocytopenia in the context of contraceptive initiation, highlighting considerations for specific methods.

Initiation and follow-up of contraception: The CDC's Selected Practice Recommendations for Contraceptive Use (SPR) provide valuable guidance for initiating and monitoring contraception in women with autoimmune disorders. Blood pressure assessment, pelvic examinations, sexually transmitted infections (STIs) screenings, past and current medical history, and disease-specific evaluations, especially assessment of aPLs status, are emphasized (18). Follow-up visits and coordination with primary rheumatologic care are recommended to ensure effective contraceptive management (19).

In conclusion, selecting appropriate contraceptive methods for women with autoimmune and systemic inflammatory

disorders requires a comprehensive assessment of disease activity, thrombotic risks, medication interactions, and individual needs of patients. Collaborative efforts between rheumatologists, gynecologists, and reproductive health specialists are crucial for providing safe and effective contraceptive care.

### Acknowledgments

The authors thank the scholars whose publications used to compose this study.

### Conflicts of interest:

Authors declared no conflict of interest

### Funding

No financial support was received for this study.

### Ethical considerations

N/A.

### Code of ethics

N/A.

### Authors' contribution

MS and EM contributed substantially in the conception and design of the study. EM and SA conducted the search process. ZM, SM and EM carried out the data collection. EM and SA drafted the first version of the manuscript. MS reviewed the manuscript critically for important intellectual content. All authors reviewed the article and approved its content.

### References

1. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. *Arthritis Care & Research*. 2015; 67(3): 313-325.
2. Sammaritano LR. Contraception in patients with rheumatic disease. *Rheumatic Disease Clinics*. 2017; 43(2): 173-188.
3. Oliveira FR, Valim V, Pasoto SG, Fernandes M, Lopes M, Fialho S. recommendations of the Brazilian Society of Rheumatology for the gynecological and obstetric care of patients with Sjogren's syndrome. *Advances in Rheumatology*. 2021; 61: 54.
4. Chighizola CB, Clowse M, Meroni PL, Andreoli L, Tincani A, Wallenius M, et al. The SPROUT study: A survey on current management practice of reproductive aspects in women of childbearing age with systemic autoimmune rheumatic diseases. *Autoimmunity Reviews*. 2023: 103376.
5. Rojas-Villarraga A, Torres-Gonzalez J-V, Ruiz-Sternberg A-M. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. *PLoS One*. 2014; 9(8): e104303.
6. Oliveira FR, Valim V, Pasoto SG, Fernandes MLMS, Lopes MLL, Souza Fialho SCdM, et al. 2021 recommendations of the Brazilian Society of Rheumatology for the gynecological and obstetric care of patients with Sjogren's syndrome. *Advances in Rheumatology*. 2021; 61: 54.
7. Culwell KR, Navarro GM. Contraception for women with rheumatologic disease. *Contraception for the Medically Challenging Patient*. 2014: 307-320.
8. Britton LE, Alspaugh A, Greene MZ, McLemore MR. An Evidence-Based Update on Contraception: A detailed review of hormonal and nonhormonal methods. *The American journal of nursing*. 2020; 120(2): 22.
9. Gilbert EL, Ryan MJ. Estrogen in cardiovascular disease during systemic lupus erythematosus. *Clinical therapeutics*. 2014; 36(12): 1901-1912.
10. Andreoli L, Bertias G, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Annals of the Rheumatic Diseases*. 2017; 76(3): 476-485.
11. Bianchi P, Guo S-W, Habiba M, Benagiano G. Utility of the Levonorgestrel-Releasing Intrauterine System in the Treatment of Abnormal Uterine Bleeding and Dysmenorrhea: A Narrative Review. *Journal of Clinical Medicine*. 2022; 11(19): 5836.
12. Farr SL, Folger SG, Paulen ME, Curtis KM. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. *Contraception*. 2010; 82(1): 64-71.
13. Benagiano G, Benagiano M, Bianchi P, D'Elios MM, Brosens I. Contraception in autoimmune diseases. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2019; 60: 111-123.
14. Fayed HL, Hatem H, Kamal H, Mahmoud I. Rheumatoid arthritis activity and severity in relation to commonly used contraceptive

- methods in a cohort of Egyptian female patients. *International Journal of Clinical Rheumatology*. 2017; 12: 168.
15. Shapiro SC. Contraception, Abortion & Rheumatic Disease after Dobbs. 2022 [Available from: <https://www.the-rheumatologist.org/article/contraception-abortion-rheumatic-disease-after-dobbs> .
  16. Williams WV. Hormonal contraception and the development of autoimmunity: a review of the literature. *The Linacre Quarterly*. 2017; 84(3): 275-295.
  17. Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. *Autoimmunity Reviews*. 2019; 18(11): 102395.
  18. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. US selected practice recommendations for contraceptive use, 2016. *Morbidity and Mortality Weekly Report: Recommendations and Reports*. 2016; 65(4): 1-66.
  19. López JAM, Vivar MLG, Cáliz R, Freire M, Galindo M, Hernández MV, et al. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding. *Reumatología Clínica (English Edition)*. 2017; 13(5): 264-281.